Elucidation of the role of 27-hydroxycholesterol in chronic obstructive pulmonary disease

Research Project

Project/Area Number	25860652
Research Category	Grant-in-Aid for Young Scientists (B)
Allocation Type	Multi-year Fund
Research Field	Respiratory organ internal medicine
Research Institution	Wakayama Medical University
Principal Investigator	Kikuchi Takashi 和歌山県立医科大学, 医学部, 助教 (40649050)
Project Period (FY)	2013-04-01 – 2016-03-31
Project Status	Completed (Fiscal Year 2015)
Budget Amount *help	¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000) Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000) Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000) Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Keywords	閉塞性肺疾患 / 27-hydroxycholesterol
Outline of Final Research Achievements	We showed that 27-hydroxycholesterol (27-OHC) augmented the release of MMP-2 and MMP-9 in lung fibroblasts. 27-OHC-augmented MMPs release was promoted by nitrosative-stress-mediated NF-κB activation and subsequent TGF-β1 release. Diseased human lung fibroblasts from patients with COPD were significantly more susceptible for the 27-OHC-induced release of MMPs than normal adult human lung ﬁbroblasts. This is the first report that showed 27-OHC augmented MMPs release and nitrosative stress. 27-OHC has the potential to be the original biomarker and therapeutical target of COPD.

Report

(4 results)